Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Imugene ( (AU:IMU) ) has shared an update.
Imugene Limited announced that its abstract on azer-cel, an allogeneic CD19 CAR T therapy, has been selected for oral presentation at the 67th American Society of Hematology Annual Meeting in Florida. This selection highlights the clinical interest in allogeneic CAR T approaches and provides an opportunity for Imugene to present new insights from their ongoing study on relapsed or refractory large B-cell lymphoma, potentially impacting the company’s industry positioning and stakeholder engagement.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene is a clinical-stage immuno-oncology company focused on developing novel immunotherapies aimed at activating the immune system to treat and eradicate tumors. Their pipeline includes an allogeneic cell therapy CAR T drug, azer-cel, targeting CD19 for blood cancers, and oncolytic virotherapy for various cancers in combination with standard treatments and emerging immunotherapies.
YTD Price Performance: -70.99%
Average Trading Volume: 2,758,458
Technical Sentiment Signal: Sell
Current Market Cap: A$108M
See more insights into IMU stock on TipRanks’ Stock Analysis page.